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Abstract
Background: Hypoxia-inducible factor-1 alpha (HIF-1a) maybe an important regulatory factor for angiogenesis of
small cell lung cancer (SCLC). Our study aimed to investigate the effect of HIF-1a on angiogenic potential of SCLC
including two points: One is the effect of HIF-1a on the angiogenesis of SCLC in vivo. The other is the regulation
of angiogenic genes by HIF-1a in vitro and in vivo.
Methods: In vivo we used an alternative method to study the effect of HIF-1a on angiogenic potential of SCLC by
buliding NCI-H446 cell transplantation tumor on the chick embryo chorioallantoic membrane (CAM) surface. In vitro
we used microarray to screen out the angiogenic genes regulated by HIF-1a and tested their expression level in
CAM transplantation tumor by RT-PCR and Western-blot analysis.
Results: In vivo angiogenic response surrounding the SCLC transplantation tumors in chick embryo chorioallantoic
membrane (CAM) was promoted after exogenous HIF-1a transduction (p < 0.05). In vitro the changes of
angiogenic genes expression induced by HIF-1a in NCI-H446 cells were analyzed by cDNA microarray experiments.
HIF-1a upregulated the expression of angiogenic genes VEGF-A, TNFAIP6, PDGFC, FN1, MMP28, MMP14 to 6.76-,
6.69-, 2.26-, 2.31-, 4.39-, 2.97- fold respectively and glycolytic genes GLUT1, GLUT2 to2.98-, 3.74- fold respectively. In
addition, the expression of these angiogenic factors were also upregulated by HIF-1a in the transplantion tumors
in CAM as RT-PCR and Western-blot analysis indicated.
Conclusions: These results indicated that HIF-1a may enhance the angiogenic potential of SCLC by regulating
some angiogenic genes such as VEGF-A, MMP28 etc. Therefore, HIF-1a may be a potential target for the gene
targeted therapy of SCLC.
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Background
Hypoxia inducible factor-1 alpha (HIF-1a) is a member
of the HIF-1 gene family, it is highly expressed in
hypoxic conditions and degraded in normoxic condition
[1,2]. HIF-1a activation is a common feature of tumors
[3,4]; it is generally more pronounced in aggressive
tumors [5] and can be an independent predictor of poor
prognosis in certain types of cancer [6]. This is primarily
due to the fact that HIF-1a plays a major role in the
development of a characteristic tumor phenotype influ-
encing growth rate, angiogenesis, invasiveness, and
metastasis. Of these characteristics, angiogenesis is the
most significant because it is essential for the other bio-
logical characteristics [7]. Several investigation about the
angiogenesis of some kinds of malignant tumors such as
breast and prostate cancer [8], head and neck cancer [9]
have demonstrated that it is an intricate multistep and
temporally ordered process that involves a great number
of genes, modifiers and pathways regulated by HIF-1a.
Some of these genes are directly induced by HIF-1a,
such as NOS(nitric oxide synthases), angiogenic and vas-
cular growth factors(VEGF) and urokinasetype plasmi-
nogen activator receptor (uPAR). Others are indirectly
regulated by HIF-1a and might be influenced by sec-
ondary mechanisms. SCLC exhibits high expression
levels of HIF-1a [10,11] and early hematogenous metas-
tasis to other organs, such as brain, kidney, and liver,
which relies on tumor angiogenesis [12]. However, the
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effect of HIF-1a on the angiogenic potential and regula-
tion of angiogenic gene expression levels that influence
this biological process have not been previously
reported. In our study, we will use appropriate experi-
mental methods to investigate these points.
For the in vivo study, we used the chick embryo chor-
ioallantoic membrane (CAM) as the experimental
model. CAM is an easily accessible and highly vascular-
ized structure lining the inner surface of the egg shell
that has been used to measure the invasive and angio-
genic properties of tumor cell xenografts for the loss of
the mature immune system in the early phase of devel-
opment [13,14]. Several studies have investigated the
formation of CAM vessels at different stages of develop-
ment [15-17]. In this model, tumor cells are grafted to
the CAM to reproduce the tumor characteristics in vivo
including tumor mass formation, angiogenesis, and
metastasis. Tumor explants and tumor cell suspensions
have been shown to invade the chorionic epithelium
and to form visible masses within 3 d to 5 d. After
implantation and transplantation, the tumors can be
macroscopically observed in the CAM [18]. Moreover,
the growth and angiogenic responses of the transplanta-
tion tumors can be examined using microscopy and
quantified for analysis. Therefore, the CAM model is an
ideal model for cancer research [19,20].
With regard to the possible difference of growth and
angiogenic responses after transduction by HIF-1a or
siHIF-1a into SCLC cells, we think that HIF-1a may
regulate the expression of some genes responsible for
these biological characteristics. To identify these genes
and confirm if HIF-1a influence the growth, invasive-
ness and angiogenesis of SCLC cells by up- or down-
regulation of these genes involved in these activity, first
we screened human gene chips containing 54614 unique
cDNA clones using cDNA prepared from mRNA of
SCLC cells in all the experimental groups. After these
genes were screened out we continued to measure their
expression levels in the xenografts formed by SCLC
cells in the CAM by Transcriptase-polymerase chain
reaction (RT-PCR) and Western-blot analysis. This
study investigated the effect of HIF-1a on the angio-
genic potential of the SCLC cells at histological, mor-
phological, and molecular levels. Furthermore, this study
demonstrated that HIF-1a may be used as a potential
target for the treatment of SCLC in the future.
Methods
Cell culture and transduction with Ad5-HIF-1a and Ad5-
siHIF-1a
The NCI-H446 cell line was obtained from the Ameri-
can Type Culture Collection (ATCC; CAS; cell bank of
Shanghai Institutes for Biological Sciences) and was cul-
tured in RPMI-1640 medium (Sigma-Aldrich Co., St.
Louis, MO, USA) supplemented with 10% fetal bovine
serum (FBS; Hyclone) and 100-μg/ml kanamycin at 37°C
in a humidified atmosphere containing 5% CO2 and 20%
O2. The medium was routinely changed 2 d to 3 d after
seeding. Cells were detached with trypsin/EDTA (Gib-
coBRL, Paisley, UK) and were resuspended in a 1:1 solu-
tion of serum-free RPMI-1640 medium to a final
concentration of approximately 5 × 105 cells/10 μl. The
appropriate transduction conditions of adenovirus
(lengthen of time and multiplicity of infection-MOI)
should be cleared for the analysis of microarry and PCR.
The high transduction efficiency of Ad5 (a tumor-speci-
fic and replication-defective adenovirus used as the con-
trol vector) could reduce experimental error and
resulted in differential expression levels of HIF-1a in
Ad5-HIF-1a and Ad5-siHIF-1a treatment groups, which
was favorable to investigate the effect of HIF-1a on the
growth of NCI-H446 cells. We infected the cells by Ad5
and Ad5-siRNA and further eliminated the effect of ade-
novirus vector and non-targeting control siRNA. Ad5-
EGFP, Ad5-siRNA-EGFP, Ad5-HIF-1a-EGFP and Ad5-
siHIF-1a-EGFP adenoviruses were obtained from the
Viral-Gene Therapy Department of Shanghai Eastern
Hepatobiliary Surgery Hospital [21,22]. The sequences
of the HIF-1a primers were as follows: upstream
sequence (5’CTAGCTAGCTAGACCATG GAGGGC
GGC’3) and downstream sequence (5’CGGGATCCT-
TATCAGTTAACTTGATC C’3). The sequences of the





CC’3). As for Ad5-siHIF-1a, the pSilencer adeno 1.0-
CMV system was purchased from Ambion for adeno-
virus construction. According to the manufacturer pro-
tocol deno-siHIF-1a was packaged and produced as the
adenoviral backbone plasmid and the shuttle vector con-
taining the siRNA template were linearized with PacI
and then recombined in HEK-293 cells. After 10 days,
Ad-siHIF-1a was obtained [22]. For the transduction
experiments, cells were cultured in 6-well plates and
were exposed to viral supernatants in the absence of
cytokines and serum with different MOI. The titers of
the Ad5-HIF-1a-EGFP and Ad5-siHIF-1a-EGFP adeno-
viruses were 1 × 1010 pfu/L. Cytometry was used to cal-
culate the cell number and the efficiency of transduction
was estimated by determining the percentage of
enhanced green fluorescence protein (EGFP)-positive
cells. The appropriate MOI was chosed using the follow-
ing formula: MOI = titer (pfu) × viral fluid (L)/cell num-
ber. When the MOI was 50, the transduction efficiency
was more than 95% and expression was stable in a
transduction experiment for 60 h (Figures 1A and 1B).
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In order to eliminated the effect of empty vector Ad5
and non-targeting control siRNA: Ad5-siRNA on HIF-
1a mRNA expression and SCLC cells growth, transduc-
tion of NCI-H446 cells with Ad5 and Ad5-siRNA were
carried out. In five selected time stages we found that
empty vector Ad5 and Ad5-siRNA had no significant
effect on the HIF-1a mRNA expression(Figure 1C). We
selected the group(MOI = 50) for the high and stable
transduction efficiency in the following experiments.
HIF-1a mRNA levels in the NCI-H446 cells were mea-
sured by real-time PCR in our laboratory. The expres-
sion of HIF-1a mRNA was the highest in the Ad5-HIF-
1a -treated cells and lowest in the Ad5-siHIF-1a-treated
cells 60 h after transduction (Figure 1D). In addition,
exogenous HIF-1a transduction significantly induced
NCI-H446 cells growth and empty vector Ad5 and Ad5-
siRNA transduction had no significant effect on the
growth of NCI-H446 cells (Figure 1E).
In vivo CAM assay
For the in vivo study, we used the CAM as an experi-
mental vector to evaluate different tumor parameters.
Four-day-old fertilized white leghorn chicken eggs (50
g-65 g) were incubated under 60% relative air humidity
at 37°C and were rotated hourly with standing. On the
third day of incubation, an irregular window (2 × 1.5
cm) was made on the top of the air chamber at the
large, blunt end of the egg. A 21-gauge needle was used
to puncture the endoconch membrane. Sterilized saline
(0.1 ml) was administrated by injection to detach the
endoconch membrane from the CAM. A second air
chamber, called the flase air chamber (distinguished
from the autospecific air chamber), was set up between
these two membranes. The transduced and non-trans-
duced cell suspensions (5 × 104 cells/μl) were gently
pipetted onto the CAM surface with a transfer pipette.
The eggs were then placed in the incubator. The
engraftment growth was observed, and the tumor
volume was calculated from day 4 to day 17 using the
following formula: tumor volume (mm3) = (tumor
length × width2)/2. The following three experimental
groups that contained 12 samples each were used in this
study: NCI-H446 group (control group), NCI-H446/Ad
group, NCI-H446/Ad-siRNA group, NCI-H446/HIF-1a
group, and NCI-H446/siHIF-1a group. The results were
analyzed using a t-test and one-way ANOVA. The
angiogenic responses were evaluated from day 8 to day
17 using a stereomicroscope connected to an image
Figure 1 Transduction of NCI-H446 cells with Ad5. Chosing transduction condition and the effect on NCI-H446 cells growth by HIF-1a. (A)
Five different multiplicities of infection (MOI: 20, 30, 40, 50, and 70) were tested in the transduction experiment (60 h). The transduction
efficiency was the highest when the MOI was 50 (*p < 0.05 represents MOI50 vs. MOI40; **p < 0.05 represents MOI50 vs. MOI70). (B)
Transduction efficiency of NCI-H446 cells with Ad5-EGFP after 60 h (MOI = 50; 200 ×). (C) After the cells were transduced with Ad5 and Ad5-
siRNA(MOI = 50), the mRNA expression level of HIF-1a was measured in the indicated time period by real-time PCR (*p > 0.05 represents NCI-
H446/Ad5 group vs control group; ▲p > 0.05 represents NCI-H446/Ad5- siRNA group vs control group;) (D)After the cells were transduced with
Ad5-HIF-1a and Ad5-siHIF-1a (MOI = 50), the mRNA expression level of HIF-1a was measured in the indicated time period by real-time PCR (*p
< 0.05 represents NCI-H446/HIF-1a group and NCI-H446/siHIF-1a group, 60 h vs. 48 h; ** p < 0.05 represents NCI-H446/HIF-1a group and NCI-
H446/siHIF-1a group, 60 h vs. 72 h). (E) Growth curve of the cells in five groups. After transduction with Ad5 and Ad5-siRNA, the trendency of
growth curve had no significant change. After transduction with HIF-1a, the growth curve of NCI-H446 cells shifted to the left with the growth
of cells entering the period of logarithmic growth. After transduction with Ad5-siHIF-1a, however, the growth curve shifted to the right (*p >
0.05 represents NCI-H446/Ad5 or NCI-H446/Ad5-siRNA group vs. NCI-H446 group; **p < 0.01 represents NCI-H446/HIF-1a group vs. NCI-H446
group; ***p < 0.01 represents NCI-H446/siHIF-1a group vs. NCI-H446 group).
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analyzer system in NCI-H446/Ad group (control group),
NCI-H446/HIF-1a group, and NCI-H446/siHIF-1a
group. Several parameters of angiogenesis, such as vessel
area and number of vessel branches, were quantified by
MIQAS quantified system analysis. For each study
group, approximately 10 to 15 domains were selected
for vessel quantification, and the mean values of the ves-
sel number and vessel density were calculated.
Histological assessment of transplantation tumors in the
CAM
In order to identify the pathobiological characteristics of
the transplantation tumors in the CAM, hematoxylin-
eosin (HE) staining was used to evaluate the structure of
the tumors and peripheral tissues. Neuron-specific eno-
lase (NSE) is a specific marker of neuroendocrine tumor
cells, such as SCLC cells, and is used as an important
monitoring index in clinical diagnosis and therapy.
Immunohistochemical analysis was performed to mea-
sure the expression of NSE. All tumor tissue sections
from the paraffin blocks were deparaffinized, and endo-
genous peroxidases were inhibited with 0.3% hydrogen
peroxide in methanol for 30 min. Antigen retrieval was
achieved using 0.05% protease XIV at 37°C for 5 min.
Sections were then incubated at room temperature for 1
h with a mouse anti-human NSE primary antibody (1:40
dilution; Wuhan Boster Biological Engineering Technol-
ogy Co. Ltd.), rinsed with PBS, and incubated with a
biotin-conjugated rabbit anti-mouse secondary antibody
at room temperature for 45 min. The sections were sub-
sequently incubated with a streptavidin-biotin-peroxi-
dase complex (Vectastain ABC kit, Vector Laboratories,
Burlingame, CA, USA) at room temperature for 45 min.
The reaction was visualized using chromogen diamino-
benzidine (DAB) for 10s. Sections were counterstained
with haematoxylin, dehydrated, and permanently
mounted.
RNA extraction, microarray hybridization and data
analysis
For the in vitro study, cDNA microarray technology was
used to evaluate the change in the gene expression pro-
file of NCI-H446 SCLC cells after transduction with
Ad5-HIF-1a or Ad5-siHIF-1a and screened out the
angiogenesis-related genes with differential expression.
NCI-H446 cells were transduced with Ad5-HIF-1a or
Ad5-siHIF-1a for 60 h. Afterwards, cells were washed
with ice-cold phosphate-buffered saline (PBS) and lysed
with 3 ml Trizol (Invitrogen, San Diego, CA, USA).
Total RNA was extracted and purified using the
RNAeasy kit according to the manufacturer’s protocol
(Qiagen, USA). The concentration of total RNA was
measured with Biophotometer (Eppendorf, Germany)
and the quality of purified RNA was confirmed by
agarose gel electrophoresis. cDNA was then synthesized
from each RNA sample using a SuperScript kit (Invitro-
gen), and the cDNA was used as a template for the pre-
paration of biotin-labeled cDNA according to the
GeneChip Labeling Kit protocol. The biotin-labeled
cDNA was hybridized with a GeneChip (Human Gen-
ome U133 plus 2.0), washed, and stained with phycoery-
thrin-streptavidin according to the manufacturer’s
protocol. The microarray contained 54614 human gene
probe sets, each of which consisted of 11 probe pairs
corresponding to a single mRNA transcript. After saved
as raw image files all the datas were converted into
probe sets and analyzed by the software GCOS base on
the method of normalization. Annotation by Unigene
database http://www.ncbi.nlm.nih.gov/unigene, gene
number, gene symbol and gene description were carried
out using the database http://strubiol.icr.ac.uk/extra/
mokca/ and Affymetrix databases [23]. The expression
levels of angiogenic genes were presented as the ratio of
the levels in the Ad5-HIF-1a group or Ad5-siHIF-1a
group to the Ad5 control group. Ratio values greater
than a 2-fold increase or decrease (p < 0.05) was consid-
ered to be significant expression changes. The primary
data sets are all available at the following website:
http://www.ncbi.nlm.nih.gov/gene
Transcriptase-polymerase chain reaction (RT-PCR) analysis
We used RT-PCR to detect the expression of angiogenic
genes obtained from microarray data in the transplanta-
tion tumor and CAM. On day 17 of incubation the
angiogenic reaction reached the most intense level as
explaining in the section of result, so we chosed the
tumors of this day to detect. RT-PCR was performed
using an RNA PCR kit (AMV) ver 3.0 according to the
manufacturer instructions (TaKaRa). Total RNA was
extracted from transplantation tumor and CAM as
described above. Level of mRNA expression of human
and chicken angiogenic factors were evaluated by PCR
using specific primers for human and chicken tran-
scripts. The relative amount of the each PCR product
was normalized to b-actin. Specific primers of these
transcripts were designed by Primer Premier 5.0 (Table
1) and were synthesized by Shanghai Sangon Biological
Engineering Technology & Services Co. The PCR pro-
gram of angiogenic genes and b-actin consisted of 30
cycles of a denaturation step at 95°C for 30 seconds, an
annealing step at 60°C for 30 seconds and an extension
step at 75°C for 30 seconds followed by a final extension
at 72°C for 5 minutes. PCR products were electrophor-
esed on a 1% agarose gel containing ethidium bromide.
The band density was measured using the software
Alpha Image 2000. The mRNA levels of the selected
genes were normalized to b-actin to produce arbitrary
units of relative transcript abundance.
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Western blot analysis
On day 17 of incubation, the transplantation tumors and
peripheral tissues of the CAM were harvested and
homogenized in lysis buffer (50-mmol/L Tris, pH 7.4;
100-μmol/L EDTA; 0.25-mol/L sucrose; 1% SDS; 1%
NP40; 1-μg/ml leupeptin; 1-μg/ml pepstatin A; and 100-
μmol/L phenylmethylsulfonylfluoride) at 4°C. The pro-
tein was electrophoresed on SDS poly-acrylamide gels
and transferred to a PVDF membrane. The membranes
were then blocked at room temperature for 1 h with 5%
non-fat milk in Tris-buffered saline containing Tween
20 (TBST) followed by incubation with rat anti-human
and rat anti-chicken primary antibodies against VEGF-A
(Wuhan Boster Biological Engineering Technology Co.
Ltd.) overnight at 4°C. The membranes were subse-
quently incubated with goat anti-rat peroxidase- conju-
gated secondary antibodies. Immunoreactivity was
detected by an enhanced chemiluminescence kit and
was captured on X-ray film.
Statistical analysis
All values were presented as means ± standard deviation
(SD). The Student’s t-test or one-way ANOVA was used
to compare the parameters between the different study
groups. P-values less than 0.05 were considered statisti-
cally significant. The statistical analyses were performed
by the Windows SPSS 13.0 software.
Results
Implantation of cells on CAM in vivo
The CAM was well-developed, and the vessels rapidly
increased at day 7 (Figures 2A, B, and 2C). The NCI-
H446 cell suspensions were implanted on the side of the
CAM facing the window. The cell suspensions invaded
across the capillary plexus and formed a visible mass on
the side of the chicken embryo (Figures 2D and 2E).
The chicken embryo tissue was eliminated, and the
CAM with the transplantation tumor is shown in Figure
2F. The morphological and pathological characteristics
of the tumor are shown in Figure 2G, and 2 its periph-
eral vessel is shown in Figure 2H. After sections were
stained with an antibody specific for the human NSE
protein, it was observed that the SCLC transplantation
tumor cells were irregularly arranged, and that the
nuclei were round or oval. Moreover, several tumor
cells presented karyokinesis. Human NSE (shown by the
yellow DAB stain) was distributed around the nucleus
or in the intercellular space. In addition, human NSE
expression was also observed around the vessel wall of
the tumor (Figure 2I). As NSE is a specific marker of
neuroendocrine tumor cells, such as SCLC cells, we ver-
ified that the transplantation tumor cells in the CAM
were derived from SCLC.
Chick embryo death was determined by the matte
appearance of the CAM and yolk sac. The survival rate
of chick embryos after the implantation of cells without
transduction onto CAM was 92.5% (74 of 80), and the
survival rate of chick embryos after implantation of cells
transduced with Ad5-HIF-1a was 81.25% (65 of 80).
Moreover, the chick embryo survival rate after the
implantation of cells transduced with Ad5-siHIF-1a was
91.25% (73 of 80). Diffuse patches of NCI-H446 cells
were observed in the CAM by the third day after






VEGF-A sense 5’-TGGAAGAAGCAGCCCATGAC-3’ 59 375
antisense 5’-GCACTAGAGACAAAGACGTG-3’
IL-6 sense 5’-TCAATGAGGAGACTTGCCTG-3’ 55 410
antisense 5’-GATGAGTTGTCATGTCCTGC-3’
PDGFC sense 5’-GCCTCTTCGGGCTTCTCC-3’ 56 395
antisense5’-TTACTACTCAGGTTGGATTCCGC-3’
FN1 sense 5’-CGAAATCACAGCCAGTAG-3’ 51 278
antisense 5’-ATCACATCCACACGGTAG-3’
MMP28 sense 5’-CAAGCCAGTGTGGGGTCT-3’ 56 252
antisense 5’-TAGCGGTCATCTCGGAAG-3’
MMP14 sense 5’-ATGTCTCCCGCCCCA-3’ 60 678
antisense 5’-TCAGACCTTGTCCAGCAGG-3’
GLUT1 sense 5’-CGGGCCAAGAGTGTGCTAAA-3’ 62 283
antisense 5’-TGACGATACCGGAGCCAATG-3’
GLUT2 sense 5’-CCTGAATGCCAAGGGAATCCGG-3’ 48 368
antisense 5’-
GCCAGATGAGGTAATCAATCATAG-3’
GAPDH sense 5’-AGAAGGCTGGGGCTCATTTG-3’ 57 258
antisense 5’-AGGGGCCATCCACAGTCTTC-3’
Chicken
VEGF-A sense 5’-GTCTACGAACGCAGCTTCTG-3’ 62 265
antisense 5’-TCACATGTCCAAGTGCGCAC-3’
IL-6 sense 5’- TTGATGGACTCCCTAAGGC-3’ 50 395
antisense 5’-GATTCGGGACTGGGTTCTC-3’
PDGFC sense 5’-TTCTCAACCTGGATTCTGC-3’ 52 355
antisense 5’-AATGGTGTCAGTTCGCTTC-3’
FN1 sense 5’-ACCAACATTGACCGCCCTAA-3’ 56 458
antisense 5’-AATCCCGACACGACAGCAGA-3’
MMP28 sense 5’-TGACATCCGCCTGACCTT-3’ 57 376
antisense 5’-GTCCTGGAAGTGAGTGAAGACC-3’
MMP14 sense 5’-CGTGTTCAAGGAGCGGTGGC-3’ 61 114
antisense 5’-TAGGCGGCGTCGATGCTGT-3’
GLUT1 sense 5’-CACTGTTGTTTCGCTCTTCG-3’ 42 316
antisense 5’-AATGTACTGGAAGCCCATGC-3’
GLUT2 sense 5’-AGTTTGGCTACACTGGAG-3’ 60 436
antisense 5’-AGGATGGTGACCTTCTCC-3’
GAPDH sense 5’-CTTTCCGTGTGCCAACCC-3’ 65 108
antisense 5’-CATCAGCAGCAGCCTTCACTAC-3’
Tm - annealing temperature
Length - the number of bp in the PCR products
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implantation, but tumors were not large enough to be
accurately measured until the fourth day in all three
experimental groups. As shown in Figure 3A, the
tumors in the HIF-1a transduction group grew more
rapidly when compared to the control group (p < 0.01).
The tumors in the siHIF-1a transduction group grew
slower than the control group (p < 0.01). This result
was in agreement with the growth of NCI-H446 cells in
vitro. The same circumstance was presented from the
three growth curves showing that tumor volume
increased nearly exponentially from day 4 to day 10 but
slowly from day 14 to day 17 as the growth curves
became flat. This data suggests that more mature
immune systems inhibited the tumor growth to some
extent. With regard to angiogenesis, the vessels in the
NCI-H446/HIF-1a group were larger and more dense
(Figure 3C) when compared to the peripheral vessels
around the tumors in the NCI-H446 group (Figure 3B).
However, the vessels in the NCI-H446/siHIF-1a group
were less dense (Figure 3D) when compared to the per-
ipheral vessels around the tumors in the NCI-H446
group (Figure 3B). Beside these we also compared the
transplantation tumors between NCI-H446 group, NCI-
H446/Ad group(Figure 3E) and NCI- H446/Ad-siRNA
group(Figure 3F) and no significant difference could be
found in the angiogenic reaction between three groups.
We also found that empty adenovirus vector and non-
targeting control siRNA transduction had no significant
effect on the growth of tumors(Figure 3G).
The angiogenic image was captured (Figure 4A) and
converted to grayscale (Figure 4B). We then eliminated
the background of the graph (Figure 4C) and marked
the vessels for quantification (Figure 4D). Our results
indicated that on day 17 of incubation the angiogenic
reaction reached the most intense level. NCI-H446 cells
stimulate angiogenesis and the cells transduced with
HIF-1a significantly promote the angiogenic effect. In
contrast, the blockade of HIF-1a by Ad5-siHIF-1a
Figure 2 Macroscopic examination of the CAM and implanted human NCI-H446 cells. The entire experimental process from the
implantation of NCI-H446 cells on the CAM and the formation of the transplantation tumor is shown. (A) Irregular window made in the egg
shell of a 7-day-old chick embryo. (B) Elimination of the chick embryo in the CAM was observed. (C) The CAM was peeled for the assay. (D)
Diagram of the technique for the implantation of NCI-H446 cells onto the CAM. (E) Diagram of the technique for the formation of the
transplantation tumor. (F) The transplantation tumor (white mass was pointed by the tip) was formed on the side facing the chick embryo. (G-H)
Histological evaluation of the transplanted tumor on the CAM by hematoxylin-eosin staining is shown:(G) The structure of the transplantation
tumor and peripheral vessels (50 ×). (H) Pathological appearance of the transplantation tumor (200 ×). (I) Specific analysis was carried out by
immunohistochemistry for the expression of NSE. The cellular nucleus was irregular, and positive expression for NSE was found in the
intercellular substance or endochylema (400 ×).
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inhibited the angiogenic effect (Table 2). In addition we
also found that two parameters showed the similar
increasing trends along with the growth of transplanta-
tion tumor and the time of transduction by HIF-1a
(Table 2).
Regulation of angiogenic gene expression by HIF-1a
To evaluate the effect of HIF-1a on the gene expres-
sion profile, we used the comparative analysis algo-
rithm provided by Genespring to compare the effect of
HIF-1a among the three groups (Ad5, Ad5-HIF-1a,
and Ad5-siHIF-1a). Among the genes with differential
expression (more than 2 fold), we selected 15 genes
(Table 3) associated with angiogenesis. We found that
VEGF-A, which is a known target gene of HIF-1a, was
significantly increased by more than 6 fold after trans-
duction by Ad5-HIF-1a and reduced by approximately
4 fold after transduction by Ad5-siHIF-1a. HIF-1a also
increased the expression of several inflammatory fac-
tors, such as interleukin 6 (IL6), tumor necrosis factor
alpha-induced protein 6 (TNFAIP6), and interleukin 1
receptor type I (IL1RI). These results indicated that
angiogenesis in SCLC induced by HIF-1a may be
related to inflammatory responses because the expres-
sion levels of several corresponding inflammatory
Figure 3 Growth of the transplantation tumor. The growth curves of the transplantation tumors in the three groups are shown. Data are
presented as means ± SD. (A) The growth curves of transplantation tumors in the NCI-H446/HIF-1a group shifted left, and the growth curves
shifted right in the Ad5-siHIF-1a group (*p < 0.01 represents NCI-H446/HIF-1a group vs. NCI-H446 group; **p < 0.01 represents NCI-H446/siHIF-
1a group vs. NCI-H446 group). (B) A transplantation tumor from the NCI-H446 group (10 d after implantation). (C) A transplantation tumor from
the NCI-H446/HIF-1a group (10 d after implantation). (D) A transplantation tumor from the NCI-H446/siHIF-1a group (10 d after implantation). (E)
A transplantation tumor from the NCI-H446/Ad5 group (10 d after implantation). (F) A transplantation tumor from the NCI-H446/Ad5-siRNA
group (10 d after implantation). (G) Comparing to the growth curves in NCI-H446 group the tendency of the curves in NCI-H446/Ad5 group and
NCI-H446/Ad5-siRNA group had no significant changes. (*p > 0.05 represents NCI-H446 group vs. NCI-H446/Ad5 group; **p > 0.01 represents
NCI-H446/Ad5-siRNA group vs. NCI-H446 group).
Figure 4 Angiogenesis quantification of CAM. The entire process
of angiogenesis quantification on the CAM was divided into four
steps. (A) The image of one special domain in the CAM was
collected for the assay. (B) The background of the image was
cleaned up. (C) The profiles of the vessels for the assay were
deepened. (D) The result of the MIQAS quantified system analysis
for the number of vessel branch points as marked by the red
points.
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factors were upregulated. Matrix metalloproteinase-28
(MMP-28) and matrix metalloproteinase-14 (MMP-14)
are important members of the MMP family, and
matrix degradation is the precondition of angiogenesis
in tumors. The upregulation of MMP-28 and MMP-14
indicated that HIF-1a may promote matrix degrada-
tion to induce angiogenesis in SCLC. HIF-1a also
induced other angiogenic factors, such as tenascin C
(TNC), platelet derived growth factor C (PDGFC),
fibronectin 1 (FN1), myocardin (MYOCD), and heme
oxygenase decycling 1 (HMOX1). In contrast, HIF-1a
decreased the expression levels of the following genes:
suppressor of cytokine signaling 2 (SOCS2), insulin-
like growth factor binding protein 3 (IGFBP3), insulin-
like growth factor 1 receptor (IGF1R), and cysteine-
rich angiogenic inducer 61 (CYR61). The most signifi-
cant downregulation of gene expression was found in
the SOCS2 gene. Besides these, two glycolytic genes
glucose transporter 1(GLUT1) and glucose transporter
2 (GLUT2) were upregulated by HIF-1a to 2.98 and
Table 2 Quantification of vessel area and the number of vessel branches around the transplantation tumor
day 8 day 11 day 14 day 17
Vessel length (pixels)
Control (n = 10 × 4) 2106 ± 143 1967 ± 113 1457 ± 135 2183 ± 156
NCI/H446(n = 10 × 4) 2452 ± 117 2564 ± 96* 2687 ± 103* 2798 ± 135*
NCI/H446/HIF-1a(n = 15 × 4) 2742 ± 83 2814 ± 154 2910 ± 137§ 2994 ± 124§
NCI/H446/siHIF-1a(n = 12 × 4) 2331 ± 53# 2268 ± 106# 2236 ± 162# 2203 ± 116#
Vessel Branch points
Control (n = 10 × 4) 76 ± 5 82 ± 9 73 ± 8 89 ± 5
NCI/H446(n = 10 × 4) 92 ± 7 101 ± 11 105 ± 6* 117 ± 7*
NCI/H446/HIF-1a(n = 15 × 4) 116 ± 16 123 ± 11§ 128 ± 9§ 134 ± 21§
NCI/H446/siHIF-1a(n = 12 × 4) 82 ± 5# 87 ± 6# 92 ± 11# 102 ± 13#
The MIQAS quantified system was used for the quantification of the two vessel parameters around the transplantation tumor in the CAM. Data are presented as
means ± SD.
*Significant difference from group controls at p < 0.05 by use of paired sample t-test
§Significant difference from group controls at p < 0.05 by use of one-way ANOVA
#significant difference from group controls at p < 0.05 by use of one-way ANOVA
Table 3 The effect of HIF-1a on angiogenic gene expression
UniGeneID Gene name Gene Symbol Fold change
(ratio ≥ 2, p < 0.05)
A B
Hs.143250 Tenascin C (hexabrachion) TNC 5.28 -3.23
Hs.654458 Interleukin 6 (interferon, beta 2) IL6 5.29 -2.27
Hs.73793 Vascular endothelial growth factorA VEGF-A 6.76 -3.98
Hs.437322 Tumor necrosis factor, alpha-induced protein 6 TNFAIP6 6.96 -4.75
Hs.570855 Platelet derived growth factor C PDGFC 2.26 -3.21
Hs.701982 Interleukin 1 receptor, type I IL1R1 2.64 -2.21
Hs.203717 Fibronectin 1 FN1 2.31 -2.57
Hs.567641 Myocardin MYOCD 3.03 -2.08
Hs.517581 Heme oxygenase (decycling) 1 HMOX1 2.64 -2.73
Hs.687274 Matrix metallopeptidase 28 MMP28 4.39 -3.67
Hs.2399 Matrix metallopeptidase 14 MMP14 2.97 -2.24
Hs.473721 Glucose transporter 1 GLUT1 2.98 -2.16
Hs.167584 Glucose transporter 2 GLUT2 3.74 -2.05
Hs.485572 Suppressor of cytokine signaling 2 SOCS2 -6.06 3.06
Hs.450230 Insulin-like growth factor binding protein 3 IGFBP3 -4.02 2.17
Hs.653377 Insulin-like growth factor 1 receptor IGF1R -2.00 2.89
Hs. 8867 Cysteine-rich, angiogenic inducer, 61 CYR61 -3.03 2.18
cDNA microarray analysis was used to screen angiogenic genes with differential expression (more than 2.0-fold) between the following two comparison groups:
Ad5 vs. Ad5-HIF-1a and Ad5 vs. Ad5-siHIF-1a.
A = Ad5 vs. Ad5-HIF-1a; 11 genes were upregulated and 4 genes were downregulated by HIF-1a
B = Ad5 vs. Ad5-siHIF-1a; 4 genes were upregulated and 11 genes were downregulated by siHIF-1a (contrasting the A group)
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3.74 respectively, so we concluded that HIF-1a maybe
upregulate the glycolysis reaction of SCLC.
RT-PCR analysis for angiogenic factors in CAM
We used RT-PCR analysis to study the angiogenic
potential of NCI-H446 SCLC cell implanted on the
CAM. We found that HIF-1a increased mRNA expres-
sion levels of human and chicken VEGF-A, TNFAIP6,
PDGFC, FN1, MMP28, MMP14(Figure 5A-C) GLUT1,
GLUT2 (Figure 6A-C), but decreased the expression of
human SOCS2 and IGFBP3. However, no changes in
the expression of chicken angiogenic factors SOCS2 and
IGFBP3 were observed in transplantation tumors of
CAM (Figure 5A-C).
Western blot analysis for VEGF-A expression
VEGF is regarded as the gold standard of angiogenesis,
and it has the most important role in the angiogenic
process in tumors. VEGF-A is a member of the VEGF
family, and it is a target gene of HIF-1a. In this study,
both human and chicken VEGF-A protein expression
levels were high in the CAM tissue of the HIF-1a trans-
duction group as compared to the other groups (Figures
7A, B, and 7C). Similar to the real-time PCR results, we
presumed that angiogenesis in the CAM induced by the
transplantation tumor was affected by human VEGF-A
to a greater extent than by chicken VEGF-A.
Discussion
Gene transduction of SCLC cells by HIF-1a
With regard to SCLC, a common pulmonary solid
tumor, angiogenesis regulated by HIF-1a may have an
important role in determining tumor phenotypes. In
order to recapitulate the effect of HIF-1a in a hypoxic
environment, we overexpressed human HIF-1a in SCLC
NCI-H446 cells with the gene vector Ad5-based
Figure 5 RT-PCR analysis of human and chicken angiogenic factors mRNA. Microarray analysis was performed to screen out the angiogenic
factors affected by HIF-1a in SCLC cells (table 2). Afterwards, RT-PCR analysis was used to detect the expression of angiogenic factors affected by HIF-
1a in the transplantation tumors of CAM in vivo. (A), Human and chicken VEGF-A, TNFAIP6, PDGFC, FN1, MMP28, MMP14, SOCS2 and IGFBP3 mRNA
expression: Representative images of three independent experiments (Lane 1: control group-no human mRNA expression, Lane 2: transplantation
tumor of NCI-H446 cells transduction by empty vector Ad5-NCI-H446 cells group, Lane 3: ransplantation tumor of NCI-H446 cells with transduction by
HIF-1a-NCI-H446/HIF-1a group, Lane 4: transplantation tumor of NCI-H446 cells with transduction by siHIF-1a-NCI-H446/siHIF-1a group). (B and C),
Relative expression levels of mRNA in NCI-H446/HIF-1a group and NCI-H446/siHIF-1a group compared with that in control group and NCI-H446 cells
group (p < 0.05).
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transduction system. The type 5 adenovirus-based trans-
duction system is a transient expression system that
allows protein expression in transduced cells to reach a
higher level than the level found in non-transduced cells
in a short period of time, which can reduce the possibi-
lity of experimental error to some extent [24]. Accord-
ing to our previous study, we used the appropriate
plaque-forming unit (pfu) (MOI = 50) for a high expres-
sion level of HIF-1a [23] in this study. A gene-specific
siRNA, which exhibited stronger suppressive effects
than antisense oligonucleotides [25], was used to silence
the expression of HIF-1a and to further confirm the
effects of HIF-1a on NCI-H446 cells and transplantation
tumors. The in vitro study demonstrated that cells
transduced with HIF-1a grew more rapidly than control
cells, and cells transduced with siHIF-1a grew more
slowly than control cells. The in vivo study indicated
that the tumor formation rate of the HIF-1a transduc-
tion group was significantly higher than the rate of the
non-transduction and siHIF-1a transduction groups.
Moreover, the average tumor growth rate in the HIF-1a
gene transduction group was higher than the tumor
growth rates in the non-transduction and siHIF-1a
groups. Thus, these results suggest that HIF-1a may be
involved in promoting the progression of SCLC. Our
study further supports the previous opinion that HIF-1a
is correlated with the development of an aggressive phe-
notype in some tumor models [26], and that HIF-1a has
been identified as a positive factor for tumor growth
[27].
Figure 6 RT-PCR analysis of human and chicken glycolytic factors mRNA. RT-PCR analysis was used to detect the expression of glycolytic
factors affected by HIF-1a in the transplantation tumors of CAM in vivo. (A), Human and chicken GLUT1 and GLUT2 mRNA expression:
Representative images of three independent experiments (Lane 1: control group-no human mRNA expression, Lane 2: transplantation tumor of
NCI-H446 cells transduction by empty vector Ad5-NCI-H446 cells group, Lane 3: ransplantation tumor of NCI-H446 cells with transduction by HIF-
1a-NCI-H446/HIF-1a group, Lane 4: transplantation tumor of NCI-H446 cells with transduction by siHIF-1a-NCI-H446/siHIF-1a group). (B and C),
Relative expression levels of mRNA in NCI-H446/HIF-1a group and NCI-H446/siHIF-1a group compared with that in control group and NCI-H446
cells group (p < 0.05).
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Induction angiogenesis of SCLC cells on CAM by HIF-1a
Chicken embryos are immunodeficient during embryo-
nic development until day 19 of incubation [13]. Thus,
CAM was first adapted by many investigators as a con-
venient model to evaluate many different parameters of
tumor growth [28] and to screen antineoplastic drugs
[29,30]. Furthermore, the CAM model is an ideal alter-
native to the nude mouse model system for cancer
research because it can conveniently and inexpensively
reproduce many tumor characteristics in vivo, such as
tumor mass formation, tumor-induced angiogenesis,
infiltrative growth, and metastasis [31]. This model is
especially ideal to study tumor-induced angiogenesis
because of its dense vascular net and rapid vascular
reactivity [32]. In this study, we have successfully estab-
lished the transplantation tumor model and have clearly
shown that the avian microenvironment provided the
appropriate conditions for the growth of human SCLC
cells, as in the case when they are transplanted into
immunodeficient mice [33]. Moreover, the stroma of the
CAM may represent a supportive environment for
SCLC expansion because morphologically we could see
that the SCLC cells were implanted on the side facing
the window, invaded across the capillary plexus and
formed a visible mass on the side of the chicken
embryo.
With regard to targeted therapy of solid tumors, it is
important to find a therapeutic target that is widely
involved in many biological processes. HIF-1a is overex-
pressed in many human cancers. Significant associations
between HIF-1a overexpression and patient mortality
have been shown in cancers of the brain, breast, cervix,
oropharynx, ovary, and uterus [2,4]. However, some
scholars have suggested that the effect of HIF-1a over-
expression depends on the cancer type. For example,
associations between HIF-1a overexpression and
decreased mortality have been reported for patients with
head and neck cancer [34] and non-small cell lung can-
cer [35]. In our study, however, HIF-1a overexpression
by Ad-HIF-1a significantly enhanced the angiogenic and
invasive potential of SCLC, but transduction with Ad-
siHIF-1a inhibited these potentials. Angiogenesis in
SCLC is a key biological characteristic and an important
mediator of tumor growth rate, invasiveness, and metas-
tasis. Thus, the inhibition of angiogenesis is an effective
method for the treatment of SCLC, and many targeted
therapy drugs against angiogenesis, such as bevacizumab
[36], cedirnnib [37], and sorafenib [38], have widely
been used in clinical practice. However, the therapeutic
targets of these drugs are confined to VEGF-A and its
receptor or signaling pathway. VEGF-A is a downstream
target of HIF-1a, and it contains HREs with an HIF-1a
binding site [39]. In our study, the expression of VEGF-
A and the vascular reaction in the transplantation
tumor was significantly inhibited after the expression of
HIF-1a was downregulated by siHIF-1a. In addition to
Figure 7 Western blot analysis of the human and chicken VEGF-A protein in the CAM. In the NCI-H446/HIF-1a and NCI-H446/siHIF-1a
groups, the SCLC cells were transduced with Ad-HIF-1a or Ad-siHIF-1a (MOI = 50) for 60 h before implanting onto the CAM to form
transplantation tumors. Western blots were performed to detect the VEGF-A protein level in the tumors and peripheral tissues on day 17 of
incubation. Data are presented as means ± SD. (A) Representative images of three independent experiments (Lane A - human VEGF-A protein
expression in the tumors from the NCI-H446 group; Lane B - human VEGF-A protein expression in the tumors from the NCI-H446/HIF-1a group;
and Lane C - human VEGF-A protein expression in the tumors from the NCI-H446/siHIF-1a group) (human - * p < 0.05 group C vs. group B; ** p
< 0.05 group C vs. group D) (chicken - * p < 0.05 group C vs. group B; ** p < 0.05 group C vs. group D). (B) Representative images of three
independent experiments (Lane A - chicken VEGF-A protein expression of control group; Lane B - chicken VEGF-A protein expression in the
tumors from the NCI-H446 group; Lane C - chicken VEGF-A protein expression in the tumors from the NCI-H446/HIF-1a group; and Lane D -
Chicken VEGF-A protein expression in tumors from the NCI-H446/siHIF-1a group). (C) Densitometry analysis of the relative expression of VEGF-A
protein compared to the corresponding b-actin in each group (p < 0.05).
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VEGF-A, there are many angiogenic factors that are
directly or indirectly regulated by HIF-1a. Therefore, we
propose that targeting HIF-1a may provide a broader
inhibition of tumor angiogenesis than targeting down-
stream angiogenesis factors of HIF-1a. In the future, we
will conduct correlated research to confirm this
proposal.
Angiogenic factors regulated by HIF-1a in SCLC cells
transplantation tumor
In pervious study although the multitude of insights were
put into individual molecular effect on angiogenesis, such
as increased migration and tube formation, which may be
predicted to induce angiogenesis in vitro, these analyses
in isolated systems clearly have their limitations, espe-
cially when a large scale of interconnections and com-
plexity involved in the process of angiogenesis in vivo are
considered. Allowing for this the in vivo expression of
angiogenesis genes selected from the in vitro microarray
analysis must be confirmed. Thus, it is important to suc-
cessfully establish a simple and comprehensive model to
test how HIF-1a regulates angiogenesis genes. Some
scholars have suggested that xenograft models of tumor
cells rely more on angiogenesis than naturally occurring
tumors and that the extent of angiogenesis is dependent
on the site of implantation of the xenografts [40]. CAM
is essentially a respiratory membrane with a dense vascu-
lar net that maintains the blood-gas exchange. For abun-
dant blood supply and a special anatomical position in
the chick embryo, the CAM may provide more precise
and convincing data for angiogenic factors than other in
vivo experimental models [31].
Recent research and development for a targeted drug
for SCLC has focused on inhibiting the expression of
angiogenic factors, such as VEGF-A. However, the
microenvironment of SCLC cell growth is largely
hypoxic, and HIF-1a is the primary regulatory factor for
angiogenesis. The factors that are mediated by HIF-1a
and involved in angiogenesis of SCLC have not been
previously reported. Therefore, in our study, we initially
evaluated the effects of HIF-1a on the invasiveness of
SCLC, which precedes angiogenesis. Matrix metallopro-
teinases (MMPs) are a family of enzymes responsible for
remodeling the extracellular matrix during growth and
morphogenetic processes, which are important for
tumor invasiveness. In our study, two members of the
MMP family, MMP-14 and MMP-28, had increased
expression resulting from HIF-1a overexpression in the
in vitro microarray experiment and in the CAM experi-
ments. The increased expression of MMP-14 has been
identified as a negative predictor of survival in SCLC
[41], and the targeted drug inhibiting MMP-14 expres-
sion, marimastat [42], has been used in clinical studies.
MMP-28 is expressed at low levels in normal lung
tissue, but the expression of MMP-28 is highly increased
after cancer formation [43]. MMP-28 induces epithelial-
mesenchymal transitions (EMT), which yield tumor cells
with collagen-invasive properties allowing the invasion
of collagen matrices [44]. The upregulation of MMP-28
by HIF-1a enhances this ability.
The expression level of angiogenic factors is the gold
standard to measure the angiogenic potential of tumors,
and the inhibition of the expression of angiogenic fac-
tors is the primary treatment for SCLC. Angiogenic fac-
tors that are significantly regulated by HIF-1a in a
hypoxic microenvironment are also therapeutic target
points [45]. In addition to VEGF, FGF-2 [46], ANG-2
[47], HIF-2a [48], and PDGFC are also involved in
tumor angiogenesis. In this study, three inflammatory
factors, IL-6, TNFAIP6, and IL1R1, were upregulated by
HIF-1a. These inflammatory factors actively responded
during the process of inflammatory angiogenesis.
TNFAIP6 is the stimulating factor for TNF-a [49], and
IL-1R1 is the receptor for IL-1 [50]. IL-6 and VEGF-A
have synergistic effects in stimulating the proliferation
and invasiveness of tumors by promoting angiogenesis
[51]. Our results indicate that HIF-1a may enhance the
inflammatory reaction or stimulate the secretion of
coherent inflammatory factors to promote the angiogen-
esis of SCLC, which highlights the importance of anti-
inflammation for the treatment of SCLC as some scho-
lars have suggested [52]. In addition, the TNC, FN1, and
HMOX1 cytokines were screen out by microarray analy-
sis. TNC is an extracellular matrix protein with angio-
genesis-promoting activities, and it has specific
functions in vessel formation [53]. FN1 has been shown
to be an angiogenic cytokine involved in angiogenesis
during several pathological processes, such as psoriasis,
diabetic retinopathy, and cancer [54]. The overexpres-
sion of HMOX1 has been observed in liver cancer [55],
pancreatic cancer [56], and melanomas [57]. Targeting
these cytokines for gene therapy of SCLC in the future
requires their verification in clinical trials.
Conclusions
Overall, our results suggest that HIF-1a significantly
promotes the growth and angiogenesis of NCI-H446
cells by upregulating the expression of angiogenic genes.
Moreover, our use of the chick CAM as an in vivo
experimental model further confirms the expression of
these genes induced by HIF-1a. Tumor growth on the
chick CAM after they were grafted with human SCLC
NCI-H446 cells represents an excellent model to study
human SCLC angiogenesis. This study suggests that
HIF-1a may be a potential target in the treatment of
SCLC. In the future, we will further investigate human
SCLC progression and invasiveness, and we will screen
anti-angiogenic molecules in the CAM model to further
Wan et al. Journal of Experimental & Clinical Cancer Research 2011, 30:77
http://www.jeccr.com/content/30/1/77
Page 12 of 14
enhance the number of possible genes for SCLC tar-
geted therapies.
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